Skip to content
DataLookout
Menu

hypo-CASHNCT06695741

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: No significant improvement in efficacy was observed. Show 6 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Final enrollment: 14 participants (planned 75)
    • Primary completion date changed from estimate of Feb 1, 2027 to May 1, 2025
    • Study completion date changed from estimate of Jun 30, 2027 to Jun 30, 2025
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: terminated, suspended or withdrawn

Endpoints

Primary

Overall response rate
Timeframe: Within 3 months

Secondary (5)

Superior response rate
Overall response rate
Incidence of the adverse event
Time to achieve robust superior response
First time to response

Arms and interventions

hypo-CASHExperimental

ALG/CsA and herombopag and reduced dose of cyclophosphamide

Drugs: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy

Sites

1 site in 1 country

  • Red Blood Cell Disorders Center and Regenerative Medicine CenterTianjin, Tianjin Municipality, China